Treatment Options After CAR T Therapy for Large B-Cell Lymphoma
The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Video Player is loading.
This content originally appeared on our sister site, OncLive.
Recent Videos
Brian Kim, MBA, on the Emergence of CRISPR-Based Medicines and the Resurgence of AAV
Peter Cook, PhD, on Exploring DARIC CAR T-Cells for Autoimmune Indications
Nicholas Giovannone, PhD, on the Potential Benefits of Redosing Gene Therapy
Brian Kim, MBA, on Multiomic Single-Cell Sequencing and the Ebbs and Flows of the Gene Therapy Field
Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on the Implications of the First Successful Personalized Gene Editing Therapy
Ben Samelson-Jones, MD, PhD, on Conservative Management Following Treatment With DMD Gene Therapy Elevidys
Rebecca Ahrens-Nicklas, MD, PhD, and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on the Next Steps for Personalized Gene Editing
Roger Hajjar, MD, on Helping to Bring Preclinical Gene Therapy Research to First-In-Human Trials
Rebecca Ahrens-Nicklas, MD, PhD; and Kiran Musunuru, MD, PhD, MPH, ML, MRA, on Treating CPS1 Deficiency With Personalized Gene Editing
Nicholas Giovannone, PhD, on Using Bispecific Antibodies to Redose AAV Gene Therapy
Related Content
